Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635606 · ClinicalTrials.gov registry record
GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients
A clinical trial of Coronary Artery Disease, sponsored by Sapere Bio.
- Completed
- Registry status
- 370
- Enrollment target
- 3
- Study locations
NCT03635606: Completed study of Coronary Artery Disease, sponsored by Sapere Bio.
NCT03635606 is a study of Coronary Artery Disease that has completed, run by Sapere Bio. The registered enrollment target is 370 participants, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03635606, a study of Coronary Artery Disease, has completed, sponsored by Sapere Bio.
- COMPLETED
- Registry status
- 370 participants
- Enrollment target
- 3
- Study locations
Study Summary
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at higher risk for AKI and current risk predictor scores that are based on clinical and demographic information are inadequate. Therefore, a diagnostic test for predicting AKI risk in this clinical context would assist clinicians to optimize surgical strategy and postoperative care to prevent CSA-AKI occurrence and improve patient outcomes. The primary purpose of this study is to validate a panel of biomarkers identified in the discovery study (referred to as AKI-Sapere prognostic) to identify patients at risk for all stages of CSA-AKI.
Conditions Studied
Study Locations (3)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Maryland
- Johns Hopkins University - Baltimore
North Carolina
- WakeMed Health and Hospitals - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2023-02-28 |
What the finished NCT03635606 record still lists
NCT03635606 is an observational study that tracks outcomes without assigning an intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03635606 reports a single indexed study location in California, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03635606 about?
NCT03635606 is a clinical study titled "GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients". Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at...
What is the current status of trial NCT03635606?
This trial is currently completed. The enrollment target is 370 participants. The study started on 2020-02-24. Estimated completion is 2023-02-28.
What conditions does trial NCT03635606 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
Who is sponsoring clinical trial NCT03635606?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03635606 being conducted?
This trial has 3 study locations across California, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03635606's enrollment target sits among peer trials
370 92nd of 219 higher than 128 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI